Peripheral effects Via the AMY2 and AMY3 receptors Cagrilintide acts peripherally: Slowing of gastric emptying , stronger than with GLP-1 Suppression of postprandial glucagon , helps control postprandial glycemic spikes Modulation of bone remodeling (via AMY3), a neutral effect, but clinically monitored Synergy with GLP-1 (the mechanistic basis of CagriSema) The main innovation is the complementarity with the GLP-1 pathway : GLP-1 suppresses appetite via the arcuate nucleus of the hypothalamus (POMC neurons, AgRP/NPY inhibition) Amylin suppresses appetite via the area postrema (CGRP-like neurons) Two independent centers, two independent mechanisms
TB-500 partially replicates this function on fragment 17-23, considered the minimal active sequence
The "better" product depends on which formulation philosophy fits your priorities: higher-dose targeted actives in a filler-free capsule (FertilitySmart) or a broad-spectrum one-a-day tablet with high-street availability and a lower price (Vitabiotics)
Additionally, the mortality rate in the peptide subjects appeared to significantly decrease, with a 2-fold decrease in the Thymalin subjects, a 1.8-fold decrease in the Epithalon subjects, and 2.5-fold decrease in the subjects presented with both peptides
These results are noteworthy as it has been shown that NOS activity is necessary for calcium-induced activation of the Akt pathway